File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016

TitleEpidemiology of gout in Hong Kong: a population-based study from 2006 to 2016
Authors
KeywordsGout
Hong Kong
Epidemiology
Urate-lowering therapy
Issue Date2020
PublisherBioMed Central Ltd. The Journal's web site is located at http://arthritis-research.com/
Citation
Arthritis Research & Therapy, 2020, v. 22 n. 1, p. article no. 204 How to Cite?
AbstractObjective: To determine the incidence and prevalence of gout in the general population and the utilisation of urate-lowering therapy (ULT) among patients with gout in Hong Kong. Methods: A total of 2,741,862 subjects who attended any outpatient clinics or accident and emergency department (with or without hospitalisation) in 2005 and did not die before 2006 were identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. All subjects were followed until the end of 2016 or death. Demographics, diagnosis of gout, serum urate levels, and ULT prescriptions were retrieved from CDARS. Gout was defined by the diagnosis codes in CDARS. The serum urate levels achieved after prescribing ULT were the means of all serum urate levels measured 6 months after prescriptions. Results were analysed by R version 3.3.3 with package ‘prevalence’ version 0.4.0. Results: The crude incidence of gout increased from 113.05/100,000 person-years (PY) in 2006 to 211.62/100,000 PY in 2016. The crude prevalence of gout increased from 1.56% in 2006 to 2.92% in 2016. Only 25.55% of patients with gout were prescribed ULT in 2016. 35.8% of patients treated with ULT were able to achieve the target serum urate level of < 6 mg/dL. Conclusions: Population ageing as well as other risk factors contributed to an increase in the incidence and prevalence of gout in Hong Kong. In 2016, the crude prevalence of gout in Hong Kong was comparable to that in many western countries. However, only one in four patients with gout in Hong Kong was prescribed ULT.
Persistent Identifierhttp://hdl.handle.net/10722/290926
ISSN
2023 Impact Factor: 4.4
2023 SCImago Journal Rankings: 1.518
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTsoi, MF-
dc.contributor.authorChung, MH-
dc.contributor.authorCheung, BMY-
dc.contributor.authorLau, WCS-
dc.contributor.authorCheung, TT-
dc.date.accessioned2020-11-02T05:49:03Z-
dc.date.available2020-11-02T05:49:03Z-
dc.date.issued2020-
dc.identifier.citationArthritis Research & Therapy, 2020, v. 22 n. 1, p. article no. 204-
dc.identifier.issn1478-6354-
dc.identifier.urihttp://hdl.handle.net/10722/290926-
dc.description.abstractObjective: To determine the incidence and prevalence of gout in the general population and the utilisation of urate-lowering therapy (ULT) among patients with gout in Hong Kong. Methods: A total of 2,741,862 subjects who attended any outpatient clinics or accident and emergency department (with or without hospitalisation) in 2005 and did not die before 2006 were identified from the Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. All subjects were followed until the end of 2016 or death. Demographics, diagnosis of gout, serum urate levels, and ULT prescriptions were retrieved from CDARS. Gout was defined by the diagnosis codes in CDARS. The serum urate levels achieved after prescribing ULT were the means of all serum urate levels measured 6 months after prescriptions. Results were analysed by R version 3.3.3 with package ‘prevalence’ version 0.4.0. Results: The crude incidence of gout increased from 113.05/100,000 person-years (PY) in 2006 to 211.62/100,000 PY in 2016. The crude prevalence of gout increased from 1.56% in 2006 to 2.92% in 2016. Only 25.55% of patients with gout were prescribed ULT in 2016. 35.8% of patients treated with ULT were able to achieve the target serum urate level of < 6 mg/dL. Conclusions: Population ageing as well as other risk factors contributed to an increase in the incidence and prevalence of gout in Hong Kong. In 2016, the crude prevalence of gout in Hong Kong was comparable to that in many western countries. However, only one in four patients with gout in Hong Kong was prescribed ULT.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://arthritis-research.com/-
dc.relation.ispartofArthritis Research & Therapy-
dc.rightsArthritis Research & Therapy. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectGout-
dc.subjectHong Kong-
dc.subjectEpidemiology-
dc.subjectUrate-lowering therapy-
dc.titleEpidemiology of gout in Hong Kong: a population-based study from 2006 to 2016-
dc.typeArticle-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.emailLau, WCS: cslau@hku.hk-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.authorityLau, WCS=rp01348-
dc.identifier.authorityCheung, TT=rp01682-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s13075-020-02299-5-
dc.identifier.pmid32887668-
dc.identifier.pmcidPMC7487938-
dc.identifier.scopuseid_2-s2.0-85090511138-
dc.identifier.hkuros317690-
dc.identifier.volume22-
dc.identifier.issue1-
dc.identifier.spagearticle no. 204-
dc.identifier.epagearticle no. 204-
dc.identifier.isiWOS:000568567400002-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1478-6354-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats